Enzymotec Announces Closing Of Upsized Secondary Public Offering, Including Full Exercise Of The Underwriters' Option To Purchase Additional Shares

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MIGDAL HA'EMEQ, Israel, March 5, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY) (the "Company") today announced the closing of a registered public offering by certain selling shareholders of 5,403,685 ordinary shares at $28.00 per share, which includes 704,828 shares purchased pursuant to the full exercise of the underwriters' option to purchase additional shares. The Company did not receive any proceeds from the sale of these shares.

Help employers find you! Check out all the jobs and post your resume.

Back to news